Skip to content
Culturally and linguistically diverse, Medical Health Aged Care

Leave no one behind in the fight against hepatitis

Hepatitis Australia 5 mins read

Hepatitis Australia is calling on Australians to get tested for hepatitis B and C in light of new data analysis that shows the makeup of Australia’s hepatitis population is changing.

 

“It’s a serious concern that nearly 300,000 people in Australia live with hepatitis B and C and nearly 1,000 Australians die each year from these preventable diseases,” says Hepatitis Australia CEO Lucy Clynes.

 

“There is a simple cure for hepatitis C and treatment for hepatitis B, but many people aren’t receiving them because they’re unaware of their risk or disconnected from care.

 

This World Hepatitis Day, Hepatitis Australia is releasing a new report, If Hepatitis was 100 people, which shows that:

  • The population of people affected by hepatitis B and hepatitis C in Australia is changing
  • Many people in Australia don’t realise they are at risk – eg. 1 in 3 people living with hepatitis B don’t realise they have it.
  • People are missing out on life-saving treatment and care.

 

We’re not reaching everyone living with hepatitis C

Modern cures for hepatitis C are very effective and have minimal side effects.

“In Australia, the most common way that people got hepatitis C was through injecting drug use, so a lot of work has been done to ensure people who inject drugs are receiving the cure. That work has been really effective, which is why we’re seeing a change in the population,” Lucy Clynes says.

“While working with people who inject drugs will always be core business for community hepatitis organisations, 84 per cent of people living with hepatitis C in Australia no longer inject drugs or contracted hepatitis C in other ways. That could be things like unsafe tattooing, receiving a blood transfusion before 1990 (when screening was introduced) or getting a medical or dental procedure in a country with poor blood safety regulations. They are less likely to be interacting with services where hepatitis C is core business. We need to find new ways to reach them,” Lucy Clynes says.

Aboriginal and Torres Strait Islander peoples are disproportionately affected by hepatitis C and haven’t experienced equal benefit from the national response.  In hepatitis C outcomes, gaps are widening.

“With almost 30% of the prison population injecting while they are incarcerated, prisons are the primary sites of transmission for hepatitis C. While data isn’t available nationally yet, our analysis shows that in NSW, 40% of all hepatitis C re-treatments are delivered in prisons and needle exchange programmes are needed to prevent transmission and re-infection.

People with hepatitis B need to be connected to care

For hepatitis B there is effective treatment which reduces the likelihood of liver disease and liver cancer, but there is no cure yet.

“Nearly 220,000 people in Australia are living with hepatitis B, but less than 25% are receiving regular care. Almost half of all people with chronic hepatitis B have not received care at any time in the last 10 years,” says Lucy Clynes.

“Our analysis shows that more than half of all people living with hepatitis B might need information in languages other than English and support in culturally sensitive ways.

“While people born in Australia since the year 2000 (when hepatitis B vaccinations began being routinely offered) are protected against hepatitis B, people born before then, or those born overseas could be living with the virus and not know it because the symptoms often aren’t obvious until the liver is severely damaged.

“Pregnancy is a key time when parents with hepatitis B are diagnosed, and we need to ensure that the whole family is getting the care they need to live long and healthy lives. Nearly one in 20 babies born to mothers with hepatitis B are not receiving the vaccine in time. We need to strengthen the monitoring of the hepatitis B ‘birthdose’ vaccine.”

Viral hepatitis – what to look out for


Hepatitis B and hepatitis C are the leading causes of liver cancer globally and in Australia,
causing 90% of liver deaths.  Liver cancer mortality rates are growing faster than any other cancer in Australia.

 

Hepatitis Australia President and infectious diseases expert, Professor Joseph Doyle, says testing is easy but hepatitis symptoms can be hard to spot.

“Most people have no symptoms of hepatitis B or hepatitis C until much later, when their liver might be seriously affected,” Professor Doyle says.

 

“Routine blood tests don’t routinely screen for hepatitis – you usually have to request it. It’s a simple blood test with a follow up confirmation to see if the virus is active.

 

There is a simple cure for hepatitis C, it’s one tablet per day for up to 12 weeks.

 

“Not everyone will need treatment for hepatitis B, but if you do, it’s a tablet a day to keep the viral load low and an annual liver scan to make sure your liver remains healthy.

 

“If you think you could be at risk of hepatitis B or hepatitis C, you can speak with a GP or call HepLink, Australia’s hepatitis information service, on 1800 437 222.

 

“HepLink is a free and confidential service that connects you to your local community hepatitis organisation for information, support and treatment for hepatitis B and hepatitis C. You don’t need a Medicare Card to call HepLink,” Professor Doyle says.

 

 


Key Facts:
  • The population of people affected by hepatitis B and hepatitis C in Australia is changing
  • Many people in Australia don’t realise they are at risk – eg. 1 in 3 people living with hepatitis B don’t realise they have it.
  • People are missing out on life-saving treatment and care.
  • Landmarks around Australia lit green to highlight the need for hepatitis testing.

About us:

Hepatitis Australia is the national peak community organisation representing the needs of people affected by hepatitis B and hepatitis C. Community hepatitis organisations play a critical role in finding people at risk or living with these conditions and supporting them to get connected to care.

If Hepatitis was 100 People draws on epidemiological data and expertise of leading research organisations The Doherty Institute, The Kirby Institute and The Burnet Institute.

Key buildings around Australia will be lit up with green lights on and around Monday July 28, World Hepatitis Day, to draw attention to the need to stop hepatitis in its tracks.

HepLink Australia 1800 437 222 www.heplink.au provides free, confidential, localised information and support to anyone, anywhere in Australia. HepLink is funded by the Australian Government Department of Health, Disability and Ageing.

Australia's World Hepatitis Day 2024Download the latest factsheet

 

 

 

Find out more about World Hepatitis Day https://www.worldhepatitisday.org.au/

World Hepatitis Day is on 28 July – the birthday of Baruch S. Blumberg who won the Nobel Prize in Physiology or Medicine in 1976 for his hepatitis B research.


Contact details:

Linda Apps                0433 999 017

Grace Hogan              0493 994 523

Media

More from this category

  • Medical Health Aged Care, Women
  • 12/12/2025
  • 01:00
Breast Cancer Trials

Simple blood tests could help tailor treatment for aggressive breast cancer

Key Facts: Blood tests detecting circulating tumour DNA could help guide treatment for triple negative breast cancer patients Absence of tumour DNA in blood…

  • Contains:
  • Medical Health Aged Care
  • 12/12/2025
  • 00:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8

DUBLIN--BUSINESS WIRE-- Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833.…

  • Government Federal, Medical Health Aged Care
  • 11/12/2025
  • 14:21
Hepatitis Australia and ASHM

Australia’s leading hepatitis experts reaffirm support for birth-dose hepatitis B vaccination

Australia’s foremost hepatitis researchers and clinicians have released a joint expert statement confirming that Australia’s recommendation remains unchanged: all medically stable newborns who meet the weight threshold should receive their first dose of the hepatitis B vaccine within 24 hours of birth. The statement follows international attention after a U.S. advisory panel recommended reversing its long-standing advice that infants receive the hepatitis B vaccine at birth. Hepatitis Australia CEO Lucy Clynes said parents and healthcare professionals should remain confident in Australia’s long-standing, evidence-based approach. “Australia’s advice has not changed. The hepatitis B birth-dose vaccination is safe, effective and one of…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.